NASDAQ: SYRESpyre Therapeutics Inc Stock
$13.57+0.90 (+7.1%)
Updated Apr 21, 2025
SYRE Price
$13.57
Fair Value Price
$0.24
Market Cap
$817.94M
52 Week Low
$10.91
52 Week High
$40.49
P/E
-4.27x
P/B
1.58x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$208.02M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.18
Operating Cash Flow
-$157M
Beta
1.07
Next Earnings
May 13, 2025
Ex-Dividend
N/A
Next Dividend
N/A
SYRE Overview
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SYRE's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
SYRE
Ranked#352 of 462
Ranked#352 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.55 | A | |
| $7.66 | A | |
| $22.02 | A |
Be the first to know about important SYRE news, forecast changes, insider trades & much more!
SYRE News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SYRE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SYRE ($13.57) is overvalued by 5,581.35% relative to our estimate of its Fair Value price of $0.24 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SYRE ($13.57) is not significantly undervalued (5,581.35%) relative to our estimate of its Fair Value price of $0.24 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SYRE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SYRE due diligence checks available for Premium users.
Valuation
SYRE fair value
Fair Value of SYRE stock based on Discounted Cash Flow (DCF)
Price
$13.57
Fair Value
$0.24
Overvalued by
5,581.35%
SYRE ($13.57) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SYRE ($13.57) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SYRE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SYRE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.27x
Industry
-184.27x
Market
27.14x
SYRE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.58x
Industry
4.04x
SYRE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SYRE's financial health
Profit margin
Revenue
$0.0
Net Income
-$56.3M
Profit Margin
0%
SYRE's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$608.5M
Liabilities
$90.7M
Debt to equity
0.18
SYRE's short-term assets ($608.47M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SYRE's short-term assets ($608.47M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SYRE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SYRE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$37.2M
Investing
-$170.5M
Financing
$225.6M
SYRE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SYRE vs Biotech Stocks
Spyre Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.